Welcome to our dedicated page for Nucana news (Ticker: NCNA), a resource for investors and traders seeking the latest updates and insights on Nucana stock.
NuCana plc (NCNA) is a clinical-stage biopharmaceutical company pioneering ProTide technology to develop enhanced cancer therapeutics. This page provides investors and researchers with essential updates on clinical trials, regulatory developments, and scientific advancements related to NuCana's innovative approach to overcoming chemotherapy resistance.
Key resources include: Press releases detailing clinical progress, analyses of pipeline candidates for solid tumors, and updates on phosphoramidate chemistry applications. Users will find verified information on drug safety profiles, trial designs, and strategic collaborations.
Regular updates cover:
- Phase I-III clinical trial results
- Regulatory submissions and FDA communications
- Scientific conference presentations
- Intellectual property developments
Bookmark this page for structured access to NuCana's latest advancements in reengineering conventional chemotherapy agents through proprietary nucleotide analog technology. Check back for objective reporting on innovations designed to improve intracellular drug activation in cancer cells.
NuCana (Nasdaq: NCNA) announced that CEO Hugh Griffith and CFO Don Munoz will present at the Jefferies Global Healthcare Conference on June 6, 2024, at 12:30 PM EDT in New York, NY. The presentation will be webcast live and made available for replay in the Investors section of the NuCana website.
NuCana (Nasdaq: NCNA) announced that CEO Hugh Griffith and CFO Don Munoz will present at TD Cowen’s 5th Annual Oncology Innovation Summit on May 28, 2024, at 8:30 AM EDT. This virtual event will offer insights related to ASCO & EHA. The live webcast and replay will be accessible through the Investors section of NuCana's website.
NuCana (NASDAQ: NCNA) has released its financial results for Q1 2024, ending March 31, 2024. The company reported a net loss of £6.8 million, an improvement from £7.9 million in Q1 2023. Cash and cash equivalents stood at £12.9 million, down from £17.2 million at the end of 2023. Loss per share was £0.13, reduced from £0.15 in the comparable period.
Key developments include the full enrollment of a Phase 2 study involving 182 colorectal cancer patients and encouraging results from NUC-7738 combined with pembrolizumab in patients resistant to PD-1 inhibitors. NuCana's clinical programs, including NUC-3373 and NUC-7738, are on track for significant data readouts in 2024. The company expects its cash runway to extend into Q1 2025.
NuCana aims to announce multiple clinical data points in 2024, focusing on metastatic colorectal cancer and melanoma treatments.
NuCana plc (NASDAQ: NCNA) has announced that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Stock Market. The company had previously been notified of non-compliance due to its closing bid price falling below $1.00 for 30 consecutive business days. However, after maintaining a minimum closing bid price of $1.00 or more for 10 consecutive business days, NuCana has now met the requirement, as confirmed by a Notification Letter from Nasdaq.
FAQ
What is the current stock price of Nucana (NCNA)?
What is the market cap of Nucana (NCNA)?
